JPH11512087A - ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割 - Google Patents

ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割

Info

Publication number
JPH11512087A
JPH11512087A JP9509499A JP50949997A JPH11512087A JP H11512087 A JPH11512087 A JP H11512087A JP 9509499 A JP9509499 A JP 9509499A JP 50949997 A JP50949997 A JP 50949997A JP H11512087 A JPH11512087 A JP H11512087A
Authority
JP
Japan
Prior art keywords
peptide
adrenomedullin
cells
antibody
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP9509499A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11512087A5 (enExample
Inventor
カッティッタ，フランク
マルチネス，アルフレド
ミラー，メイ・ジーン
アンスワース，エドワード・ジエイ
フック，ウィリアム
ウォルシュ，トーマス
グレイ，カレン
マクリ，チャールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Publication of JPH11512087A publication Critical patent/JPH11512087A/ja
Publication of JPH11512087A5 publication Critical patent/JPH11512087A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
JP9509499A 1995-08-18 1996-08-16 ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割 Withdrawn JPH11512087A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US251495P 1995-08-18 1995-08-18
US60/002,514 1995-08-18
US293695P 1995-08-30 1995-08-30
US60/002,936 1995-08-30
US1317296P 1996-03-12 1996-03-12
US60/013,172 1996-03-12
PCT/US1996/013286 WO1997007214A1 (en) 1995-08-18 1996-08-16 Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006349430A Division JP4077861B2 (ja) 1995-08-18 2006-12-26 ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割

Publications (2)

Publication Number Publication Date
JPH11512087A true JPH11512087A (ja) 1999-10-19
JPH11512087A5 JPH11512087A5 (enExample) 2004-09-09

Family

ID=27357180

Family Applications (2)

Application Number Title Priority Date Filing Date
JP9509499A Withdrawn JPH11512087A (ja) 1995-08-18 1996-08-16 ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割
JP2006349430A Expired - Fee Related JP4077861B2 (ja) 1995-08-18 2006-12-26 ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006349430A Expired - Fee Related JP4077861B2 (ja) 1995-08-18 2006-12-26 ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割

Country Status (7)

Country Link
US (4) US6320022B1 (enExample)
EP (1) EP0845036B1 (enExample)
JP (2) JPH11512087A (enExample)
AT (1) ATE180832T1 (enExample)
CA (1) CA2229741C (enExample)
DE (1) DE69602756T2 (enExample)
WO (1) WO1997007214A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509575A (ja) * 2006-11-08 2010-03-25 ブラームズ アクチェンゲゼルシャフト ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化
JP2010539003A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としての、プロアドレノメデュリンの単独またはビッグガストリンｉとの組合せの使用
JP2011529479A (ja) * 2008-07-31 2011-12-08 ユニヴェルシテ ド ラ メディテラネ（エクス マルセイユ セカンド） アドレノメデュリン受容体と結合する抗体及びその薬剤としての使用
JP2013533965A (ja) * 2010-06-18 2013-08-29 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 妊娠高血圧症及び子癇前症の予後診断とリスクの評価のためのマーカー

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
AU9369098A (en) 1997-09-26 1999-04-23 Auckland Uniservices Limited Therapeutic method
EP1214600B1 (en) 1999-09-10 2005-12-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Determination of adrenomedullin-binding proteins
WO2002040571A1 (en) * 2000-11-17 2002-05-23 Lee Jin Kyu Poly (methylsilsesquioxane) copolymers and preparation method thereof
FR2821080B1 (fr) * 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
US20110087312A1 (en) * 2001-03-02 2011-04-14 Erchonia Corporatin Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy
CA2441228A1 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2003221096A1 (en) * 2002-03-19 2003-09-29 Oncorex, Inc. Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
US20040127445A1 (en) * 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
US20040121375A1 (en) * 2002-09-30 2004-06-24 Bayer Pharmaceuticals Corporation Methods for prediction and prognosis of cancer, and monitoring cancer therapy
AU2003249012A1 (en) * 2002-09-30 2004-04-23 Japan As Represented By The President Of The University Of Tokyo Genes and polypeptides relating to human myeloid leukemia
US7364719B2 (en) 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
AU2003295422B2 (en) 2002-11-07 2009-01-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A new target for angiogenesis and anti-angiogenesis therapy
US7235376B2 (en) 2003-03-28 2007-06-26 Receptor Biologix, Inc. Gastrin hormone immunoassays
US7228658B2 (en) 2003-08-27 2007-06-12 Weyerhaeuser Company Method of attaching an end seal to manufactured seeds
AU2004273057C1 (en) * 2003-09-08 2011-06-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
US8691575B2 (en) * 2003-09-30 2014-04-08 Weyerhaeuser Nr Company General method of classifying plant embryos using a generalized Lorenz-Bayes classifier
US20050108935A1 (en) * 2003-11-25 2005-05-26 Edwin Hirahara Method and system of manufacturing artificial seed coats
CA2484533C (en) * 2003-11-25 2008-12-02 Weyerhaeuser Company Systems and method of embryo delivery for manufactured seeds
CA2486289C (en) * 2003-11-25 2008-01-08 Weyerhaeuser Company Combination end seal and restraint
US20050108929A1 (en) * 2003-11-25 2005-05-26 Edwin Hirahara Method and system for creating manufactured seeds
US7555865B2 (en) * 2003-11-25 2009-07-07 Weyerhaeuser Nr Company Method and system of manufacturing artificial seed coats
US7356965B2 (en) * 2003-12-11 2008-04-15 Weyerhaeuser Co. Multi-embryo manufactured seed
US7591287B2 (en) * 2003-12-18 2009-09-22 Weyerhaeuser Nr Company System and method for filling a seedcoat with a liquid to a selected level
US7568309B2 (en) * 2004-06-30 2009-08-04 Weyerhaeuser Nr Company Method and system for producing manufactured seeds
EP2567974A3 (en) 2004-09-22 2013-05-22 Cancer Advances, Inc., Monoclonal antibodies to progastrin
US20060070145A1 (en) * 2004-09-27 2006-03-30 Carlson William C Manufactured seed having a live end seal
CA2518279A1 (en) * 2004-09-27 2006-03-27 Weyerhaeuser Company Manufactured seed having a live end seal coating
US7547488B2 (en) * 2004-12-15 2009-06-16 Weyerhaeuser Nr Company Oriented strand board panel having improved strand alignment and a method for making the same
US7654037B2 (en) * 2005-06-30 2010-02-02 Weyerhaeuser Nr Company Method to improve plant somatic embryo germination from manufactured seed
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
JP4976412B2 (ja) * 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
CN102203607A (zh) * 2008-10-31 2011-09-28 B.R.A.H.M.S有限公司 根据对心血管系统的影响将食物和/或饮料和/或饮食和/或营养疗法和/或药物进行分类的方法和测定方法
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
EP2389799A1 (en) * 2010-05-25 2011-11-30 BioMass Booster, S.L. Method for increasing plant biomass
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
JP5932279B2 (ja) * 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
US8776012B2 (en) * 2011-10-25 2014-07-08 International Business Machines Corporation Automatic scheduling of review meetings
PL3553084T3 (pl) 2011-11-16 2023-04-17 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (adm) lub fragment przeciwciała przeciwko adm lub szkielet przeciwko adm inny niż ig do profilaktyki lub zmniejszania zaburzenia czynności narządu lub niewydolności narządu u pacjenta cierpiącego na przewlekłą lub ostrą chorobę lub ostry stan
HRP20191771T1 (hr) 2011-11-16 2019-12-27 Adrenomed Ag Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije
HRP20190122T1 (hr) 2011-11-16 2019-03-08 Adrenomed Ag Protutijelo protiv adrenomedulina (adm) ili fragment protutijela protiv adm ili okosnica ne-ig protiv adm, namijenjeni reguliranju ravnoteže tekućina kod pacijenta s kroničnom ili akutnom bolešću
US9140696B2 (en) * 2011-11-16 2015-09-22 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-IG scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
JP5953108B2 (ja) * 2012-05-14 2016-07-20 ポーラ化成工業株式会社 スクリーニング方法
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
US10793626B2 (en) * 2013-12-20 2020-10-06 Angiobiomed Gmbh Adrenomedullin binder for use in therapy of cancer
EP3067093B1 (en) * 2015-03-12 2019-08-07 Fundacion Rioja Salud Use of an inhibitor of adrenomedullin for the manufacture of a drug useful in the prevention and treatment of diseases that reduce bone density
CA3064962A1 (en) 2017-05-26 2018-11-29 National Research Council Of Canada Self-assembling peptide for activating human mast cells
IL271427B2 (en) 2017-06-15 2025-08-01 Cancer Advances Inc Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
JP7366007B2 (ja) 2017-09-13 2023-10-20 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
EP3682247B1 (en) 2017-09-13 2022-02-09 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
EP3502706A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
EP3578989A1 (en) 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm for prognosis of trauma-related complications in polytrauma patients
EP4058466A1 (en) 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1994025482A1 (en) 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509575A (ja) * 2006-11-08 2010-03-25 ブラームズ アクチェンゲゼルシャフト ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化
JP2013047689A (ja) * 2006-11-08 2013-03-07 Brahms Gmbh ＭＲ−ｐｒｏＡＤＭを用いる糖尿病の診断およびリスク層化
JP2010539003A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としての、プロアドレノメデュリンの単独またはビッグガストリンｉとの組合せの使用
JP2011529479A (ja) * 2008-07-31 2011-12-08 ユニヴェルシテ ド ラ メディテラネ（エクス マルセイユ セカンド） アドレノメデュリン受容体と結合する抗体及びその薬剤としての使用
JP2015147784A (ja) * 2008-07-31 2015-08-20 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ アドレノメデュリン受容体と結合する抗体及びその薬剤としての使用
JP2013533965A (ja) * 2010-06-18 2013-08-29 セザンヌ ソシエテ パ アクシオンス シンプリフィエ 妊娠高血圧症及び子癇前症の予後診断とリスクの評価のためのマーカー

Also Published As

Publication number Publication date
US20100021469A1 (en) 2010-01-28
DE69602756T2 (de) 2000-02-10
US7101548B2 (en) 2006-09-05
DE69602756D1 (de) 1999-07-08
EP0845036A1 (en) 1998-06-03
JP4077861B2 (ja) 2008-04-23
WO1997007214A1 (en) 1997-02-27
US20070004630A1 (en) 2007-01-04
US6320022B1 (en) 2001-11-20
JP2007145850A (ja) 2007-06-14
CA2229741A1 (en) 1997-02-27
CA2229741C (en) 2012-05-08
US20020055615A1 (en) 2002-05-09
EP0845036B1 (en) 1999-06-02
ATE180832T1 (de) 1999-06-15
US7622272B2 (en) 2009-11-24
AU710662B2 (en) 1999-09-23
US7939639B2 (en) 2011-05-10
AU6776596A (en) 1997-03-12

Similar Documents

Publication Publication Date Title
JP4077861B2 (ja) ヒトの病理学及び生理学における、アドレノメジュリン（ａｍ）及び遺伝子関連産物（ｐａｍｐ）の機能的役割
US20160152674A1 (en) Tdf-related compounds and analogs thereof
TWI224620B (en) Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin D metabolism and DNAS encoding the same
JP2003508088A (ja) ５２個のヒト分泌タンパク質
JP2003514541A (ja) １８個のヒト分泌タンパク質
JP2003520572A (ja) ケラチノサイト増殖因子−２
JP2002532092A (ja) プロスタサイクリン刺激因子−２
JP2002539174A (ja) 癌および血管新生関連の疾病の治療のためのｌｄｌ様受容体リガンドを使用する組成物および方法
US20040081984A1 (en) Ocular tear growth factor-like protein
JP2002530062A (ja) １２個のヒト分泌タンパク質
CN105873950A (zh) 用于治疗和诊断癌症的抗s100a7抗体
WO2006137597A9 (ja) 新規生理物質ｎｅｓｆａｔｉｎとその関連物質、およびそれらの用途
KR20030035047A (ko) Bmp-4 유전자 발현을 이용한 편평태선 질환의 치료 및진단방법
JP2002542766A (ja) ５０個のヒト分泌タンパク質
JP2003516114A (ja) ５０個のヒト分泌タンパク質
JP2003514543A (ja) ２３個のヒト分泌タンパク質
US20040105860A1 (en) Cell modulation using a cytoskeletal protein
JP2002538811A (ja) ４９個のヒト分泌タンパク質
AU710662C (en) Functional role of adrenomedullin (AM) and the gene-related product (PAMP) in human pathology and physiology
JP2002530058A (ja) ３１個のヒト分泌タンパク質
JP2002527104A (ja) Ｔｎｆｒ関連遺伝子１２
JP2002539778A (ja) ４９個のヒト分泌タンパク質
JP2002509693A (ja) カドヘリン由来成長因子及びその使用
Chan¹t et al. snake venom protein from Deinagkistrodon acutus with anti-angiogenic and anti-inflammatory properties
JP2003513663A (ja) ２４個のヒト分泌タンパク質

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060926

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20061113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080227

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080417

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080501

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091208